Optilume: A Cost-Saving Alternative for Recurrent Anterior Male Urethral Stricture Treatment

What is it about?

The study aimed to evaluate the cost-effectiveness of the Optilume urethral drug-coated balloon compared to endoscopic management and urethroplasty for treating recurrent anterior male urethral stricture in England. A Markov model was developed, and the base case resulted in an estimated cost saving of £2502 per patient if Optilume was introduced. The analysis showed that Optilume was a cost-saving procedure compared to endoscopic management and urethroplasty in over 90% of iterations. The study concluded that Optilume is a cost-effective alternative to endoscopic management for treating recurrent anterior male urethral stricture in England.

Featured Image

Why is it important?

This research is important because it evaluates the cost-effectiveness of the Optilume urethral drug-coated balloon (DCB) compared to the standard endoscopic management for treating recurrent anterior male urethral stricture in England. The study demonstrates that Optilume is a cost-saving treatment option, resulting in an estimated cost saving of £2502 per patient if introduced in the NHS. This information can aid healthcare decision-makers in determining the most efficient treatment option for patients with this condition. Key Takeaways: 1. Optilume is a cost-saving treatment option for recurrent anterior male urethral stricture compared to endoscopic management in the NHS in England. 2. The study demonstrates a cost savings of £2502 per patient when using Optilume compared to endoscopic management. 3. Optilume is also cost-saving when compared to urethroplasty in a scenario analysis, with an estimated saving of £243 per person. 4. The analysis is based on robust model inputs from publicly available data sources, including the BNF and NHS reference costs. 5. The study has some limitations, such as the lack of robust data to inform the comparison between Optilume and urethroplasty, and the high recurrence rates reported in the ROBUST III trial compared to the United Kingdom-based OPEN trial.